Andrew Feldman, M.D., Awarded Leukemia and Lymphoma Society Research Grant
The Leukemia and Lymphoma Society has awarded a Translation Research Program grant to Andrew Feldman, M.D., for his work, “Biomarker-Based Strategies for Personalized Therapy of ALK-Negative Anaplastic Large-Cell Lymphoma.” The award provides Dr. Feldman and his team with $200,000 per year from July 1, 2018, through June 30, 2021.
About Dr. Andrew Feldman
Dr. Feldman serves as Director of the Department of Laboratory Medicine and Pathology (DLMP) Research and Innovation Office, Vice Chair of DLMP Research, and Chair of the Next-Generation Sequencing Infrastructure Subcommittee within Mayo Clinic's Center for Individualized Medicine in Rochester, Minnesota.
Dr. Feldman is a Consultant in DLMP with appointments in the Divisions of Hematopathology, Anatomic Pathology, and Experimental Pathology. He holds the academic rank of Professor of Laboratory Medicine and Pathology.
Dr. Feldman’s research interests include the genetics and biology of T-cell lymphoma and lymphoma therapeutic targets and biomarkers. His team’s long-term goal is to improve the lives of patients with lymphoma through individualized therapy guided by new theranostic laboratory tests that predict efficacy of targeted therapeutic approaches.